GSA Capital Partners’s Akebia Therapeutics AKBA Stock Holding History

GSA Capital Partners’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-182,443	Closed	-$498K	–	1633
2025 Q3	$498K	Buy	+182,443	New	+$607K	0.04%	849
2022 Q4	–	Sell	-486,568	Closed	-$154K	–	1421
2022 Q3	$154K	Buy	+486,568	New	+$191K	0.02%	1288
2022 Q2	–	Sell	-54,370	Closed	-$39K	–	1359
2022 Q1	$39K	Buy	+54,370	New	+$116K	0.01%	1345
2021 Q4	–	Sell	-254,376	Closed	-$733K	–	1382
2021 Q3	$733K	Buy	+254,376	New	+$726K	0.07%	461
2021 Q1	–	Sell	-128,626	Closed	-$360K	–	1066
2020 Q4	$360K	Buy	128,626 +38,963	+43%	+$114K	0.06%	637
2020 Q3	$225K	Buy	+89,663	New	+$787K	0.04%	931
2019 Q4	–	Sell	-26,187	Closed	-$103K	–	1407
2019 Q3	$103K	Buy	+26,187	New	+$112K	0.01%	1277
2016 Q2	–	Sell	-10,881	Closed	-$98K	–	1714
2016 Q1	$98K	Buy	+10,881	New	+$88.2K	0.01%	1584

Other funds holding AKBA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

GSA Capital Partners's AKBA Position: Q4 2025 in Review

GSA Capital Partners sold out of Akebia Therapeutics (AKBA) in Q4 2025, closing a stake of 182,443 shares — an estimated $498K sold.

GSA Capital Partners first reported a position in AKBA in Q1 2016 and held it in 8 quarters. The position peaked at $733K in Q3 2021. 165 funds tracked by Wall St. Rank hold AKBA as of Q4 2025.

GSA Capital Partners reported no remaining Akebia Therapeutics position as of Q4 2025 after selling out during the quarter.
GSA Capital Partners sold 182,443 Akebia Therapeutics shares in Q4 2025, an estimated $498K.
GSA Capital Partners first reported a position in Akebia Therapeutics in Q1 2016 and held it in 8 quarters.
GSA Capital Partners's Akebia Therapeutics position peaked at $733K in Q3 2021.
165 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q4 2025.

Based on GSA Capital Partners's 13F filing for Q4 2025, filed 6 Feb 2026.